Trials / Completed
CompletedNCT04681131
CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC
A Phase 2 Study of BA3011 Alone and in Combination With PD-1 Inhibitor in Adult Patients With Metastatic Non-small Cell Lung Cancer (NSCLC) Who Had Prior Disease Progression on a PD-1/L-1 Inhibitor, EGFR, or ALK Inhibitor.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 85 (actual)
- Sponsor
- BioAtla, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this study is to assess safety and efficacy of CAB-AXL-ADC in NSCLC
Detailed description
This is a multi-center, open-label, Phase 2 study designed to evaluate the safety, tolerability, PK, immunogenicity, and antitumor activity of BA3011, a conditionally active biologic (CAB) AXL-targeted antibody drug conjugate (CAB-AXL-ADC), alone and in combination with PD-1 inhibitor in patients with metastatic non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CAB-AXL-ADC | Conditionally active biologic anti-AXL antibody drug conjugate |
| BIOLOGICAL | PD-1 inhibitor | PD-1 inhibitor |
Timeline
- Start date
- 2021-03-17
- Primary completion
- 2025-07-09
- Completion
- 2025-07-09
- First posted
- 2020-12-23
- Last updated
- 2025-09-25
Locations
60 sites across 7 countries: United States, Greece, Hong Kong, Italy, Poland, Spain, Taiwan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04681131. Inclusion in this directory is not an endorsement.